Quick Answer
iBio, Inc. reported Total Revenue of $400.0 thousand for fiscal year 2025.
iBio, Inc. — Key Financials by Year
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|
| Total Revenue | $400.0K +77.8% |
$225.0K | $0.00 -100.0% |
$1.88M -20.5% |
$2.37M +44.7% |
$1.64M -18.8% |
| Revenue (ASC 606) | $400.0K +77.8% |
$225.0K | $0.00 | — | — | — |
| Net Income | -$18.38M +26.2% |
-$24.91M +61.7% |
-$65.01M -29.2% |
-$50.30M -116.8% |
-$23.21M -41.2% |
-$16.44M +6.6% |
| Diluted EPS | -$1.75 +73.1% |
-$6.50 +93.9% |
-$106.19 -1737.2% |
-$5.78 -92.7% |
-$3.00 | — |
| Total Assets | $23.18M -19.3% |
$28.73M -30.3% |
$41.21M -58.5% |
$99.41M -32.4% |
$146.97M +248.1% |
$42.22M +38.0% |
| Cash and Equivalents | $8.58M -39.6% |
$14.21M +230.4% |
$4.30M -81.0% |
$22.68M -70.7% |
$77.40M +40.4% |
$55.11M +1146.6% |
| Stockholders Equity | $14.88M -30.2% |
$21.32M +38.6% |
$15.38M -75.8% |
$63.48M -41.5% |
$108.58M +2644.1% |
$3.96M +60.7% |
| R&D Expense | $8.31M +60.3% |
$5.18M -49.8% |
$10.33M +5.1% |
$9.83M -1.6% |
$9.99M +179.6% |
$3.57M -34.7% |
| Operating Income | -$18.60M -11.8% |
-$16.63M +43.3% |
-$29.34M +1.2% |
-$29.70M +4.5% |
-$31.11M -122.2% |
-$14.00M +11.3% |
| Gross Profit | — | — | — | $2.17M +138.4% |
$909.0K -2.8% |
$935.0K |
| Shares Outstanding | 19.35M +124.4% |
8.62M +749.2% |
1.02M -88.4% |
8.73M +0.1% |
8.71M -93.8% |
140.07M +595.1% |
Most Recent Quarter
| Metric | Quarter Ending | Value | YoY | QoQ |
|---|---|---|---|---|
| Total Revenue | December 31, 2025 | $0.00 | -100.0% | -100.0% |
| Revenue (ASC 606) | December 31, 2025 | $0.00 | -100.0% | -100.0% |
| Net Income | December 31, 2025 | -$8.99M | -106.1% | -57.2% |
| Diluted EPS | December 31, 2025 | -$0.09 | +81.3% | +18.2% |
| Total Assets | December 31, 2025 | $64.39M | +196.8% | +0.4% |
| Cash and Equivalents | December 31, 2025 | $28.67M | +308.7% | +2.0% |
| Stockholders Equity | December 31, 2025 | $56.56M | +307.1% | +0.9% |
| R&D Expense | December 31, 2025 | $4.28M | +128.0% | +20.6% |
| Operating Income | December 31, 2025 | -$9.45M | -113.7% | -58.7% |
| Gross Profit | March 31, 2022 | $1.90M | +596.7% | +3345.5% |
| Shares Outstanding | December 31, 2025 | 30.05M | +227.8% | +48.4% |
- iBio, Inc. reported Total Revenue of $400.0 thousand for fiscal year 2025.
- iBio, Inc. showed an increase of +77.8% in Total Revenue compared to the prior fiscal year.
- iBio, Inc. reported Revenue (ASC 606) of $400.0 thousand for fiscal year 2025.
- iBio, Inc. showed an increase of +77.8% in Revenue (ASC 606) compared to the prior fiscal year.
- iBio, Inc. reported Net Income of -$18.38 million for fiscal year 2025.
- iBio, Inc. showed an increase of +26.2% in Net Income compared to the prior fiscal year.
- iBio, Inc. reported Diluted EPS of $1.75 per share (loss) for fiscal year 2025.
- iBio, Inc. showed an increase of +73.1% in Diluted EPS compared to the prior fiscal year.
- iBio, Inc. reported Total Assets of $23.18 million for fiscal year 2025.
- iBio, Inc. showed a decrease of -19.3% in Total Assets compared to the prior fiscal year.
- iBio, Inc. reported Cash and Equivalents of $8.58 million for fiscal year 2025.
- iBio, Inc. showed a decrease of -39.6% in Cash and Equivalents compared to the prior fiscal year.
- iBio, Inc. reported Stockholders Equity of $14.88 million for fiscal year 2025.
- iBio, Inc. showed a decrease of -30.2% in Stockholders Equity compared to the prior fiscal year.
- iBio, Inc. reported R&D Expense of $8.31 million for fiscal year 2025.
- iBio, Inc. showed an increase of +60.3% in R&D Expense compared to the prior fiscal year.
- iBio, Inc. reported Operating Income of -$18.60 million for fiscal year 2025.
- iBio, Inc. showed a decrease of -11.8% in Operating Income compared to the prior fiscal year.
- iBio, Inc. reported Gross Profit of $2.17 million for fiscal year 2022.
- iBio, Inc. showed an increase of +138.4% in Gross Profit compared to the prior fiscal year.
- iBio, Inc. reported Shares Outstanding of 19.35 million shares for fiscal year 2025.
- iBio, Inc. showed an increase of +124.4% in Shares Outstanding compared to the prior fiscal year.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: